Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Sanofi SA (SNY) Price & Performance

AMC ENTERTAINMENT HOLDINGS, INC.Trade

Price performance (Past 24H)

Key statistics

AMC ENTERTAINMENT HOLDINGS, INC. vs Sanofi SA — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.51 (market cap $2.14B), while Sanofi SA trades at $43.58 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 48.7× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.

AMCSNY
Market Cap
$2.14B$104.30B
Sector
MediaHealth
52-Week High
$3.15$52.34
52-Week Low
$0.95$41.33
Enterprise Value
$9.08B$124.19B
Dividend Yield
0.11%5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMC ENTERTAINMENT HOLDINGS, INC.

AMC trades at $2.465, up 1.86% on the day, with a bullish technical signal and recent earnings beats. The company reported record revenue and EBITDA in Q2 2026, with improving cash flow trends. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion. Analyst consensus is mixed with a $3.00 price target.

Outlook hinges on sustained box office recovery and cost discipline to achieve profitability. Key risks include high debt load, competitive pressures, and reliance on blockbuster films. Upside potential exists if operational improvements continue, but financial stability remains a concern for investors.

Sanofi SA

SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.

Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AMC ENTERTAINMENT HOLDINGS, INC.

AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.

Read more on AMC

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY